Inflammatory and Metabolic Biomarkers in Cardiovascular Complications with SARS-CoV-2

新型COVID-19 SARS中人们最不了解但临床上最重要的方面之一 CoV 2冠状病毒具有显著的异质性，它与感染的严重程度和 终末器官并发症的发生和死亡率。SARS CoV-2感染具有复杂的 流行病学与心血管疾病（CVD）的相互作用，并强调了这种复杂的异质性。 对CVD结果中这种异质性的生物学基础知之甚少， 同时，目前还不存在临床上有用的生物标志物来识别最高风险 需要最严格监控的病人因此，我们建议使用整合组学， 使用现有生物标本的不同多中心北卡罗来纳州队列中的EHR数据， 确定炎症，代谢和新的分子机制的作用，并确定 COVID-19患者CVD结局的生物标志物。我们建议（1）确定 不同CVD风险人群中感染严重程度的临床预测因子 因素和SARS-CoV 2感染，包括种族差异的评估;（2）确定 炎症、SARS-CoV-2相关蛋白和其他候选蛋白作为 SARS CoV-2感染患者的感染严重程度和CVD结局;（3）评估 代谢途径在SARS Co-V-2感染严重程度和CVD结果中的作用。该提案 高潜力解剖之间的异质性的分子机制CVD和 SARS CoV-2结果。重要的是，它具有很大的短期潜力， 结果，这将导致更早，更好地识别高风险患者， 监测;预防终末器官并发症和死亡率的新型治疗干预; 以及诊断和疾病进展生物标志物。

One of the most poorly understood yet clinically important aspects of the novel COVID-19 SARS CoV2 coronavirus is the marked heterogeneity that it displays with infection severity and with development of end organ complications and mortality. SARS CoV-2 infection has a complex epidemiologic interplay with cardiovascular (CVD) and highlights this complex heterogeneity. The biology underlying this heterogeneity in CVD outcomes is poorly understood and concomitantly, clinically useful biomarkers do not currently exist to identify the highest risk patients in need of the most intense monitoring. Thus, we propose to use integrated omics and EHR data in a diverse multi-center North Carolina cohort with existing biological specimens to determine the role of inflammation, metabolism and novel molecular mechanisms, and identify biomarkers of CVD outcomes in patients with COVID-19. We propose to (1) Determine the clinical predictors of infection severity in a diverse population of individuals with CVD risk factors and SARS-CoV2 infection including evaluation of racial differences; (2) Determine the role of inflammatory, SARS-CoV-2 related, and other candidate proteins as biomarkers of infection severity and CVD outcomes in patients with SARS CoV-2 infection; and (3) Evaluate metabolic pathways in SARS Co-V-2 infection severity and CVD outcomes. The proposal has high potential for dissecting the molecular mechanisms of the heterogeneity between CVD and SARS CoV-2 outcomes. Importantly, it has great short-term potential for clinically important results that will lead to earlier and better identification of high-risk patients for more intensive monitoring; novel therapeutic interventions to prevent end organ complications and mortality; and diagnostic and disease-progression biomarkers.